University of Edinburgh, Royal Infirmary of Edinburgh, UK.
Br J Cancer. 2010 Feb 16;102(4):665-72. doi: 10.1038/sj.bjc.6605532. Epub 2010 Jan 26.
Macrophage inhibitory cytokine-1(MIC-1) is a potential modulator of systemic inflammation and nutritional depletion, both of which are adverse prognostic factors in oesophago-gastric cancer (OGC).
Plasma MIC-1, systemic inflammation (defined as plasma C-reactive protein (CRP) of > or =10 mg l(-1) or modified Glasgow prognostic score (mGPS) of > or =1), and nutritional status were assessed in newly diagnosed OGC patients (n=293). Healthy volunteers (n=35) served as controls.
MIC-1 was elevated in patients (median=1371 pg ml(-1); range 141-39 053) when compared with controls (median=377 pg ml(-1); range 141-3786; P<0.001). Patients with gastric tumours (median=1592 pg ml(-1); range 141-12 643) showed higher MIC-1 concentrations than patients with junctional (median=1337 pg ml(-1); range 383-39 053) and oesophageal tumours (median=1180 pg ml(-1); range 258-31 184; P=0.015). Patients showed a median weight loss of 6.4% (range 0.0-33.4%), and 42% of patients had an mGPS of > or =1 or plasma CRP of > or =10 mg l(-1) (median=9 mg l(-1); range 1-200). MIC-1 correlated positively with disease stage (r(2)=0.217; P<0.001), age (r(2)=0.332; P<0.001), CRP (r(2)=0.314; P<0.001), and mGPS (r(2)=0.336; P<0.001), and negatively with Karnofsky Performance Score (r(2)=-0.269; P<0.001). However, although MIC-1 correlated weakly with dietary intake (r(2)=0.157; P=0.031), it did not correlate with weight loss, BMI, or anthropometry. Patients with MIC-1 levels in the upper quartile showed reduced survival (median=204 days; 95% CI 157-251) when compared with patients with MIC-1 levels in the lower three quartiles (median=316 days; 95% CI 259-373; P=0.036), but MIC-1 was not an independent prognostic indicator.
There is no independent link between plasma MIC-1 levels and depleted nutritional status or survival in OGC.
巨噬细胞抑制因子-1（MIC-1）是一种潜在的全身炎症和营养耗竭的调节剂，而全身炎症和营养耗竭是胃癌（OGC）的不良预后因素。
对 293 例新诊断的 OGC 患者（n=293）和 35 例健康志愿者（n=35）进行血浆 MIC-1、全身炎症（定义为血浆 C 反应蛋白（CRP）≥10mg/L 或改良格拉斯哥预后评分（mGPS）≥1）和营养状况评估。
与对照组相比（中位数=377pg/ml；范围 141-3786；P<0.001），患者的 MIC-1 水平升高（中位数=1371pg/ml；范围 141-39053）。胃肿瘤患者的 MIC-1 浓度高于交界处肿瘤患者（中位数=1592pg/ml；范围 141-12643）和食管肿瘤患者（中位数=1180pg/ml；范围 258-31184；P=0.015）。患者的体重平均减轻 6.4%（范围 0.0-33.4%），42%的患者 mGPS≥1 或血浆 CRP≥10mg/L（中位数=9mg/L；范围 1-200）。MIC-1 与疾病分期（r²=0.217；P<0.001）、年龄（r²=0.332；P<0.001）、CRP（r²=0.314；P<0.001）和 mGPS（r²=0.336；P<0.001）呈正相关，与卡氏功能状态评分（r²=-0.269；P<0.001）呈负相关。然而，尽管 MIC-1 与饮食摄入呈弱相关（r²=0.157；P=0.031），但与体重减轻、BMI 或人体测量学无关。MIC-1 水平处于上四分位的患者的生存率（中位数=204 天；95%CI 157-251）较 MIC-1 水平处于下三分位的患者（中位数=316 天；95%CI 259-373；P=0.036）降低，但 MIC-1 不是独立的预后指标。
在 OGC 中，血浆 MIC-1 水平与营养消耗状态或生存之间没有独立联系。
